Skip to content

Study · Randomized controlled trial · n = 52 · 2024

5 results

Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability.

Hwang S, Suk JW, Meffert H, Lerdahl A, Garvey WF, Edwards R, Delizza A, Soltis-Vaughan B, Cordts K, Leibenluft E, Blair RJR

The American journal of psychiatry29 Feb 2024Cited by 5 (Europe PMC)

PMID38419495 (opens in a new tab)PMCIDPMC10984767 (opens in a new tab)DOI10.1176/appi.ajp.20230174 (opens in a new tab)PepBankPUB-38419495
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In youths with severe irritability, intranasal oxytocin significantly improved CGI-S ratings compared with placebo.

    In plain wordsIn youths with severe irritability, oxytocin improved clinician severity ratings more than placebo did.

    Peptide
    Oxytocin
    Outcome
    DecreaseCGI-S rating of irritability severity
    Study

    n = 52

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Youths who received oxytocin showed significant improvement in CGI-S and CGI-I ratings compared with those who received placebo.
    2 context sentences
    Summary · context
    Fifty-two participants with severe irritability, as measured by a score ≥4 on the Affective Reactivity Index (ARI), with diagnoses of disruptive behavior disorders (DBDs) and/or disruptive mood dysregulation disorder (DMDD) were randomly assigned to treatment with intranasal oxytocin or placebo daily for 3 weeks.
    Summary · context
    Forty-three participants (22 in the oxytocin group and 21 in the placebo group) completed pre- and posttreatment functional MRI (fMRI) scans with the affective Stroop task.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In youths with severe irritability, intranasal oxytocin significantly improved CGI-I ratings compared with placebo.

    In plain wordsIn youths with severe irritability, oxytocin improved clinician improvement ratings more than placebo did.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedCGI-I rating of improvement
    Study

    n = 52

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Youths who received oxytocin showed significant improvement in CGI-S and CGI-I ratings compared with those who received placebo.
    2 context sentences
    Summary · context
    Fifty-two participants with severe irritability, as measured by a score ≥4 on the Affective Reactivity Index (ARI), with diagnoses of disruptive behavior disorders (DBDs) and/or disruptive mood dysregulation disorder (DMDD) were randomly assigned to treatment with intranasal oxytocin or placebo daily for 3 weeks.
    Summary · context
    Forty-three participants (22 in the oxytocin group and 21 in the placebo group) completed pre- and posttreatment functional MRI (fMRI) scans with the affective Stroop task.
  3. 03HumanRandomized controlled trialMechanism

    In youths with severe irritability, BOLD responses to emotional stimuli in the dorsomedial prefrontal cortex were reduced after oxytocin compared with placebo.

    In plain wordsIn youths with severe irritability, oxytocin reduced brain activity to emotional images in one frontal region compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseBOLD response in dorsomedial prefrontal cortex
    Study

    n = 43

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    BOLD) responses to emotional stimuli in the dorsomedial prefrontal cortex
    3 context sentences
    Summary · context
    were significantly reduced after oxytocin compared with placebo.
    Summary · context
    Fifty-two participants with severe irritability, as measured by a score ≥4 on the Affective Reactivity Index (ARI), with diagnoses of disruptive behavior disorders (DBDs) and/or disruptive mood dysregulation disorder (DMDD) were randomly assigned to treatment with intranasal oxytocin or placebo daily for 3 weeks.
    Summary · context
    Forty-three participants (22 in the oxytocin group and 21 in the placebo group) completed pre- and posttreatment functional MRI (fMRI) scans with the affective Stroop task.
  4. 04HumanRandomized controlled trialMechanism

    In youths with severe irritability, BOLD responses to emotional stimuli in the posterior cingulate cortex were reduced after oxytocin compared with placebo.

    In plain wordsIn youths with severe irritability, oxytocin reduced brain activity to emotional images in the posterior cingulate compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseBOLD response in posterior cingulate cortex
    Study

    n = 43

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    In the fMRI data, blood-oxygen-level-dependent (BOLD) responses to emotional stimuli in the dorsomedial prefrontal cortex and posterior cingulate cortex were significantly reduced after oxytocin compared with placebo.
    2 context sentences
    Summary · context
    Fifty-two participants with severe irritability, as measured by a score ≥4 on the Affective Reactivity Index (ARI), with diagnoses of disruptive behavior disorders (DBDs) and/or disruptive mood dysregulation disorder (DMDD) were randomly assigned to treatment with intranasal oxytocin or placebo daily for 3 weeks.
    Summary · context
    Forty-three participants (22 in the oxytocin group and 21 in the placebo group) completed pre- and posttreatment functional MRI (fMRI) scans with the affective Stroop task.
  5. 05HumanRandomized controlled trialMechanism

    In youths with severe irritability, the BOLD response changes after oxytocin were correlated with improvement in clinical severity.

    In plain wordsIn youths with severe irritability, brain activity changes after oxytocin went with better clinical severity.

    Peptide
    Oxytocin
    Outcome
    Not applicableCorrelation of BOLD changes with clinical severity improvement
    Study

    n = 43

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    These BOLD response changes were correlated with improvement in clinical severity.
    2 context sentences
    Summary · context
    Fifty-two participants with severe irritability, as measured by a score ≥4 on the Affective Reactivity Index (ARI), with diagnoses of disruptive behavior disorders (DBDs) and/or disruptive mood dysregulation disorder (DMDD) were randomly assigned to treatment with intranasal oxytocin or placebo daily for 3 weeks.
    Summary · context
    Forty-three participants (22 in the oxytocin group and 21 in the placebo group) completed pre- and posttreatment functional MRI (fMRI) scans with the affective Stroop task.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.